Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

PBS broadens access to COPD triple therapy and lung cancer immunotherapy

Urgent need for a national health protection strategy against bushfire smoke

Respiratory physicians placing too much emphasis on gender when diagnosing IPF

FOT better than spirometry for identifying poor asthma control

Novel therapy success for ‘untreatable’ P. aeruginosa in CF lung transplant patient

COPD

Morphine listed on PBS for chronic breathlessness in palliative care

By Michael Woodhead

27 Aug 2019

Sustained-release morphine (Kapanol) tablets will be listed on the PBS from 1 September for the management of chronic breathlessness in palliative care settings. The listing will provide subsidised treatment for symptomatic relief of chronic breathlessness in patients with advanced COPD, cardiac failure, malignancy or other causes. The restricted benefit listing on the Palliative Care Schedule ...

Already a member?

Forgot my password

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

First name: *

Last name: *

Country: *

Email: *

Password: *

Password must contain at least 8 characters including 1 letter and 1 number.

AHPRA Number: * Find my AHPRA number

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Top Stories